Immuno-oncology Novel T-cell engager AZD-9793 has improved therapeutic index Nov. 26, 2024 Researchers from Astrazeneca plc presented the discovery and preclinical characterization of AZD-9793, a novel CD8-guided T-cell engager (TCE) being developed for the treatment of hepatocellular carcinoma (HCC).Read More